Peter Dull

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen Earle, Donna M. Ambrosino, Andrew Fioré-Gartland et al. · Vaccine · 2021 · 961 citations · Full text

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

Nicoletta Gossger, Matthew D. Snape, Ly‐Mee Yu et al. · JAMA · 2012 · 277 citations

Immunology, Vaccine Hesitancy, Effective Vaccine +19

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

Robert C. Read, David Baxter, David Chadwick et al. · The Lancet · 2014 · 276 citations · Full text

Vaccination, Vaccine Safety, Vaccine Efficacy +6

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

Timo Vesikari, Susanna Esposito, Roman Prymula et al. · The Lancet · 2013 · 271 citations

Vaccinology, Vaccine Safety, Vaccination +10

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

Marı́a Elena Santolaya, Miguel L. O’Ryan, María Teresa Valenzuela et al. · The Lancet · 2012 · 262 citations

Vaccination, Vaccine Safety, Healthy Adolescents +9